YZYunwang Zhao

Yunwang Zhao

*This is an algorithmically generated author record based on publicly available information.

Yunwang Zhao has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 17 November 2026
    • Published by MDPI AG in Preprints.org
      • https://doi.org/10.20944/preprints202611.1636.v1
    Open Access

    mRNA-Lipid Nanoparticle Vaccines for Infectious Diseases: Mechanisms of Action and Translational Progress

    by Yunwang Zhao, Hongxian Cheng, Shiyi Zhou, Lei He, Chenlin Xiu, Baihai Huang, Xiongxiong Lu

    Six years after the first emergency use authorizations, mRNA-lipid nanoparticle (mRNA-LNP) vaccines have gone from a platform without a licensed product to one that supplies a large share of the world's COVID-19 and respiratory syncytial virus (RSV) vaccine doses and has completed phase 3 trials for seasonal influenza. Their performance depends on mechanisms that are being resolved with unusual speed at the level of individual cell types, receptors and molecular interactions, and several textbook assumptions have had to be revised in the process. This review follows the vaccine from the formulation vial to the germinal centre. We first describe how the RNA is engineered for efficient translation and for partial escape from cytosolic and endosomal RNA sensors, and why N1-methylpseudouridine is neither immunologically silent nor translationally neutral. We then examine how the ionizable lipid, the helper phospholipid, cholesterol and the PEG-lipid determine particle behaviour, cell uptake and endosomal release, and how the lipid and RNA components act as separable adjuvant signals. Evidence from mouse models and from human lymph node sampling is compared, with attention to the substantial species differences in innate cytokine control that limit extrapolation from mice to people. The clinical section summarizes efficacy and immunogenicity data for COVID-19, RSV and influenza vaccines, and the preclinical and early clinical status of candidates against cytomegalovirus, mpox, HIV, malaria, Nipah virus and Clostridioides difficile. Safety data are discussed in absolute terms rather than as signals alone. We close with the questions that currently block rational improvement: the molecular identity of the lipid sensor, the difficulty of separating immunogenicity from reactogenicity, the absence of a quantitative description of endosomal escape, and the design of antigens for pathogens that do not tolerate a single fixed immunogen.

  • Open Access

    Three RNA Vaccine Formats and the Lipid Problem Underneath Them

    by Yunwang Zhao, Hongxian Cheng, Shiyi Zhou, Lei He, Chenlin Xiu, Baihai Huang, Xiongxiong Lu

    Six years after the first licensed mRNA vaccine, the argument in the field is no longer whether RNA can be delivered. It is which RNA, for how long, and at what cost in reactogenicity. Three molecular formats carry most of the work now: nucleoside-modified linear mRNA, self-amplifying RNA (saRNA) and circular RNA (circRNA). Each has produced human or near-human data since 2021, and each is limited at a different step-cytosolic lifetime, innate sensing of replication intermediates, and manufacturing. Beneath all three sits the ionizable lipid, whose discovery process has itself been redesigned: combinatorial libraries, machine learning and iterative chemical evolution have compressed what once took years into months, without yet producing a molecule that separates potency from inflammation. This Review follows the three formats through their mechanistic constraints and their clinical readouts, then examines what the lipid literature of the past five years does and does not establish. We give particular weight to results that conflict, to effect sizes measured in the wrong species, and to claims that circulate without a same-condition comparison behind them.

  • Open Access

    Aptamers for Serum Biomarker Detection in Pancreatic Cancer: The Glycan Gap and the Evidence Gap

    by Yunwang Zhao, Hongxian Cheng, Shiyi Zhou, Lei He, Chenlin Xiu, Baihai Huang, Xiongxiong Lu

    Pancreatic ductal adenocarcinoma (PDAC) is lethal largely because it is diagnosed after it has spread, and the only blood marker in routine use, carbohydrate antigen 19-9 (CA19-9), is a fucosylated glycan whose synthesis depends on polymorphic fucosyltransferases. Aptamers - short single-stranded oligonucleotides selected entirely in vitro - have been proposed for two decades as the recognition element that could make PDAC detectable in serum. Here we assess that proposal against the literature of the past three years. Three conclusions emerge. First, the analytical problem is largely solved: electrochemical, plasmonic, transistor-based and amplification-coupled aptasensors now reach femtomolar to attomolar limits of detection, two to four orders of magnitude below the concentration of every circulating PDAC analyte. Second, the binding problem is not solved in the place where it matters: aptamers are selected against protein epitopes, whereas the clinically validated PDAC marker is a carbohydrate, and the glycan-recognition reagents that would close this gap remain scarce. Third, the evidence problem is untouched: almost all published aptasensors stop at case-control comparison against healthy donors, a design that cannot address the benign pancreatic diseases, diabetes and jaundice that dominate the differential diagnosis, and that inflates positive predictive value in a population where prevalence is 1-2%. We set out the analyte, recognition, selection, transduction and evidence requirements for an aptamer test that could plausibly change how PDAC is found, and argue that the field’s next advance will come from assay architecture - logic-gated, multi-analyte, single-vesicle measurement - rather than from another order of magnitude in sensitivity.

  • Open Access

    The Ionizable Lipid Trilemma: Potency, Address and Tolerability in RNA Delivery

    by Yunwang Zhao, Hongxian Cheng, Shiyi Zhou, Lei He, Chenlin Xiu, Baihai Huang, Xiongxiong Lu

    Lipid nanoparticles are the default vehicle for RNA medicines, and the ionizable lipid is the component that makes them work. Its protonatable amine is asked to perform three unrelated tasks: to condense a polyanionic cargo at pH 4, to disrupt the endosomal membrane at pH 5-6, and to remain invisible to innate immunity and to the complement system. All three depend on the same chemical variable - the density, basicity and presentation of the amine - so they cannot be optimized independently, and a decade of medicinal chemistry has consisted largely of trading one against another. Here we argue that this coupling, rather than potency, is the central problem of the field. We examine what the protonation switch does and does not determine, show that tissue address is set by the protein corona rather than by the lipid, and trace how the amine headgroup became the platform’s adjuvant. We then set out a modular design logic in which address, escape and silence are encoded in separate components, and specify the measurements that would show whether such particles actually work.

  • Open Access

    Aptamers at the Clinical Interface: Molecular Recognition, Device Architecture and the Evidence Required for Adoption

    by Yunwang Zhao, Hongxian Cheng, Shiyi Zhou, Lei He, Chenlin Xiu, Baihai Huang, Xiongxiong Lu

    Aptamers, short single-stranded oligonucleotides selected to bind a chosen target, have for three decades been presented as programmable substitutes for antibodies. The past five years have changed the terms of that comparison. Selection can now be performed inside living cells, generative models propose binders that were never present in the starting library, and electrochemical aptamer switches report drug concentrations in human interstitial fluid with minute resolution over a day. In parallel, population-scale aptamer proteomics has made the aptamer a workhorse of biomarker discovery rather than a curiosity of the assay laboratory. Clinical adoption nevertheless remains uneven, and the reasons are mechanistic rather than merely engineering-related. An aptamer is a conformational ensemble whose binding equilibrium is re-weighted by ions, competing proteins and surface chemistry, so an affinity measured in selection buffer is a poor predictor of behaviour in blood. Here we examine the molecular principles that govern aptamer recognition, the device architectures that convert binding into a clinical readout, and the clinical evidence accumulated since 2021. We argue that the rate-limiting step has moved from molecular discovery to the construction of evidence that regulators, payers and clinicians can audit, and we propose a framework for generating it.

  • Open Access

    Aptamer-Based Screening and Detection of Serum Biomarkers for Lung Cancer

    by Yunwang Zhao, Hongxian Cheng, Shiyi Zhou, Lei He, Chenlin Xiu, Baihai Huang, Xiongxiong Lu

    Lung cancer remains the leading cause of cancer death worldwide, and most patients are still diagnosed after symptoms appear, when curative treatment is no longer possible. Low-dose computed tomography (LDCT) reduces mortality in high-risk smokers, yet uptake is low, eligibility criteria exclude the large never-smoker populations of East Asia, and false-positive findings generate downstream harm. A blood test that could triage who needs imaging, or rule out disease in indeterminate nodules, would therefore have substantial clinical value. Aptamers - short single-stranded oligonucleotides selected in vitro and produced by chemical synthesis - are attractive as the recognition layer of such a test because they can be generated against native membrane proteins and glycans, are thermostable and can be labelled site-specifically at low cost. Here we review the serum biomarker landscape in lung cancer, the chemistry that makes aptamers usable in serum, the selection strategies that now deliver picomolar binders within days, and the transduction architectures that convert binding into a clinical readout. We argue that analytical sensitivity is no longer the limiting factor: the field’s bottleneck has moved upstream to matrix-adapted affinity and downstream to prospective, blinded validation.

  • Open Access

    Circular RNA in Lipid Nanoparticles: From Molecular Engineering to First-in-Human Testing

    by Yunwang Zhao, Hongxian Cheng, Shiyi Zhou, Lei He, Chenlin Xiu, Baihai Huang, Xiongxiong Lu

    Circular RNAs (circRNAs) were, until a decade ago, a by-product of transcriptome profiling. They are now drug candidates. A covalently closed backbone removes the termini that exonucleases and cap-dependent decay require, and lipid nanoparticles (LNPs) turn that molecular property into a pharmacological one by carrying the RNA into the cytoplasm of a chosen cell. Between 2021 and 2026 the field moved from reporter-gene proof of concept to nine first-in-human programmes, five of which encode a CD19 chimeric antigen receptor and one of which has completed. We argue that the central question is no longer whether circRNA can be made and delivered, but which of its claimed advantages survive in vivo, and at what cost in manufacturing complexity. We examine performance determinants at three coupled levels, the molecule, the particle and the biological context, and set out the manufacturing, analytical and regulatory problems that will decide whether circularity becomes a general platform property or a niche solution.

  • Open Access

    Aptamer Interfaces for Serum-Based Gastric Cancer Detection: From Molecular Recognition to Clinical Decision

    by Yunwang Zhao, Hongxian Cheng, Shiyi Zhou, Lei He, Chenlin Xiu, Baihai Huang, Xiongxiong Lu

    Gastric cancer is the fifth most commonly diagnosed malignancy and the fifth leading cause of cancer death worldwide, and it remains lethal chiefly because it is detected late. Endoscopic screening demonstrably works where it is deployed at scale, but endoscopy cannot be extended to the several hundred million people who would need it; a blood test that stratifies risk before endoscopy is therefore the only realistic route to population-level early detection. Aptamers-short, chemically synthesizable nucleic acid ligands-are attractive recognition elements for such a test, and more than a decade of work has produced hundreds of aptasensors that detect gastric cancer serum markers with impressive analytical sensitivity. Almost none has reached clinical use. Here we argue that this impasse is not a problem of affinity, nor of limit of detection, but of interface design. We resolve aptamer-based serum diagnostics into four coupled interfaces-molecular recognition, the serum matrix, signal transduction and clinical evidence-and show that each has been optimized locally while the constraints they impose jointly have been ignored. We then specify a reference architecture and a minimum evidence standard for a gastric cancer serum aptamer test, and identify the five measurements that would move the field from demonstration to deployment.

  • Open Access

    Lipid Nanoparticle-Encapsulated mRNA Encoding CagW, a Conserved Component of the Helicobacter pylori Type IV Secretion System, Protects Mice Against H. pylori Challenge

    by Yunwang Zhao, Hongxian Cheng, Shiyi Zhou, Lei He, Chenlin Xiu, Baihai Huang, Xiongxiong Lu

    Background: Roughly one person in two carries Helicobacter pylori, a pathogen classified by the World Health Organization as a group I carcinogen, and the steady loss of antibiotic efficacy has made prophylaxis an urgent rather than an optional goal. No mRNA vaccine against this organism has yet been tested in the clinic, and CagW, a conserved inner-membrane subunit of the H. pylori type IV secretion system (T4SS), has never been evaluated as an mRNA-encoded antigen. Methods: A codon-optimised construct carrying a signal peptide, the CagW coding sequence and a human IgG Fc tag was synthesised, transcribed into mRNA, encapsulated in lipid nanoparticles (LNPs) and shown to direct antigen expression in HEK293T cells. C57BL/6 mice received three intramuscular doses of CagW-Fc mRNA-LNPs (5 µg mRNA each) at 14-day intervals; animals given alum alone, luciferase mRNA-LNPs or CagW protein adsorbed to alum served as comparators. Humoral readouts (IgG, IgG1, IgG2a, IgM, IgA and secretory IgA), lymphocyte proliferation, CD4+/CD8+ subsets, intracellular IFN-γ, IL-4 and IL-17A and circulating cytokines were quantified before challenge, and protection was assessed after live challenge. Results: The formulation (93.2 nm; PDI 0.13; approximately 90% encapsulation) produced CagW-specific protein in vitro. Vaccination raised high-titre CagW-specific IgG (maximal on day 42), IgM and mucosal sIgA, and drove Th1/Th2-type cellular activation (IL-2, IL-4, IL-12, IFN-γ and IL-17A). After challenge, immunised animals carried markedly fewer gastric bacteria and showed lower urease activity than controls. Conclusions: CagW-Fc mRNA-LNPs are therefore a credible mRNA vaccine platform for H. pylori and warrant further preclinical development.

  • Open Access

    Advances and Translational Challenges in mRNA–Lipid Nanoparticle Vaccines Against Helicobacter pylori: From Rational Antigen Design to Mucosal Immunity

    by Yunwang Zhao, Hongxian Cheng, Shiyi Zhou, Lei He, Chenlin Xiu, Baihai Huang, Xiongxiong Lu

    Helicobacter pylori chronically infects more than half of the global population and is the sole bacterium classified as a Group 1 carcinogen by the International Agency for Research on Cancer. Despite decades of effort, no prophylactic H. pylori vaccine has reached the market, largely because conventional subunit and whole-cell candidates failed to induce durable, mucosa-protective T-helper 1 (Th1)/Th17 immunity in humans. The clinical success of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA–lipid nanoparticle (mRNA-LNP) vaccines has re-energized nucleic-acid vaccine research and provided a validated, scalable delivery platform. This review synthesizes the emerging mechanistic rationale and early preclinical evidence evaluating whether mRNA-LNP technology can address key bottlenecks in H. pylori vaccine development: cytoplasmic antigen expression naturally favors major histocompatibility complex (MHC) class I/II presentation and CD8⁺/Th1 responses (notably, recent human and murine evidence demonstrates that cytotoxin-associated gene A [CagA]-specific gastric CD8⁺ tissue-resident memory T [TRM] cells control early H. pylori infection), multi-antigen and conserved-epitope designs can be generated rapidly by reverse vaccinology, and the LNP carrier itself acts as an intrinsic innate immune adjuvant. We summarize the principal candidate antigens (urease subunit B [UreB], CagA, vacuolating cytotoxin A [VacA], neutrophil-activating protein [NAP], H. pylori adhesin A [HpaA], and γ-glutamyl transpeptidase [GGT]), dissect LNP composition and intracellular trafficking, and critically appraise the nascent body of preclinical H. pylori mRNA and nanocarrier studies published between 2021 and 2026—specifically distinguishing two recent in vivo mRNA-LNP preprints (encoding full-length UreB or UreB₁₉₉–₃₃₈ cytokine/immunoglobulin Z [IgZ] fusions) from peer-reviewed in silico multi-epitope mRNA and self-amplifying RNA (saRNA) designs, LNP-adjuvanted recombinant UreB/NapA protein vaccines, all-trans retinoic acid-loaded gut-tropic nanovaccines, and oral/lipid DNA vaccine benchmarks. We also reconcile classic evidence that bacterial clearance can proceed in B-cell-deficient mice via MHC class II-restricted CD4⁺ T cells with the ancillary role of functional adhesion- and urease-blocking antibodies, and we examine critical safety and immunopathological constraints—including post-immunization gastritis, oncogenic CagA EPIYA motif detoxification, and target-population stratification (uninfected children versus infected adults). We conclude that while mRNA-LNP represents a promising exploratory modality for an H. pylori vaccine, the current experimental evidence base remains narrow and preliminary; peer-reviewed validation of in vivo Th17 induction, antigen breadth, mucosal delivery route, and long-term durability in non-human primate and human challenge models will be required to establish clinical feasibility.